Cuidatech
Cuidatech1About
What does Cuidatech do?
Cuidatech offers a free service that organizes medication treatment through WhatsApp reminders for patients and real-time shared tracking for caregivers. It aims to eliminate the logistical burden of managing chronic conditions, ensuring timely medication intake and providing peace of mind to those who care for others. The platform is designed for both individuals managing their own health and those supporting loved ones, with no app downloads required.
Is Cuidatech trustworthy and reputable?
StartupHub's Data Trust & Reputation score for Cuidatech is 34 out of 100, based on site security posture and privacy practices.
When was Cuidatech founded?
Cuidatech was founded in 2026.
What industry does Cuidatech operate in?
Cuidatech operates in HealthTech, Patient Engagement, Messaging Platform, WhatsApp Integration, Caregiver Support, Digital Health.
AI-powered platform for healthcare providers to manage patient WhatsApp messages efficiently.
AI-powered platform for personalized weight management and health coaching.
Clinical Trial Discovery by ENSCORE.
An independent research reference providing accessible, accurate, and transparent information on bioactive peptides and peptide science.
Medbytes provides doctors with a personalized platform for high-impact medical research and news in their specialty.
SYLARIS™ offers premium wearable wellness patches and clinical-grade skincare designed for effortless, intentional, and beautifully designed self-care rituals.
A research organization quantifying impact-focused investments using advanced AI methods to create rigorous, comparable metrics.
An interoperable digital health network leveraging AI to enable data exchange and improve healthcare delivery.
An entrant is a company tagged HealthTech whose domain was first registered in the window, counted from registry records in the StartupHub directory. 6 of them registered in the last 30 days. Registry detection runs two to three weeks behind registration, so recent weeks are a floor.
No comments yet. Be the first to share your take.